DURAGESIC-50
LOE ApproachingNDATRANSDERMALFILM, EXTENDED RELEASE
Approved
Aug 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 6h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DURAGESIC-50 is a transdermal extended-release film formulation approved in 1990 for chronic pain management. The product delivers active pharmaceutical ingredient through the skin over an extended period. Patient indications and mechanism of action are not publicly disclosed in available data.
LOE Approaching
Product approaching loss of exclusivity; expect defensive commercial strategy and potential team downsizing as generic competition intensifies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (150 mg/850 mg) With Respect to the Individual Components of Canagliflozin (1 x 300 mg) and Metformin IR Tablets (2 x 850 mg) in Healthy Volunteers
Started Sep 2011
64 enrolled
Healthy
Career Relevance
DURAGESIC-50 represents a mature franchise with limited growth opportunity and no linked job openings. Career roles on this product are primarily defensive, focused on market share retention and managed transition to post-LOE environment.
Brand Manager
Worked on DURAGESIC-50 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.